Citi Sees Advantage For Tesaro Despite Broad Lynparza Label By: TalkMarkets August 18, 2017 at 07:00 AM EDT Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro. Read More >> Related Stocks: Astrazeneca Plc ADR Clovis Oncology Inc Tesaro Inc